MGCD265-101

Phase: 
I

Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies

The purpose of this research study is to find the highest safe dose of the drug MGCD265 that can be given to participants with advanced cancer. The safety of this drug, and the effect that it has on the participants disease and your body will also be studied. MGCD265 is a drug that works by blocking proteins that are important for cancer cells to grow. MGCD265 also prevents the growth of new blood vessels that help cancer tumors grow and spread. MGCD265 an investigational agent. This means that MGCD265 is not approved by the Food and Drug Administration (FDA).

Are you Eligible? (Inclusion Criteria)

1. Patients with advanced metastatic or unresectable malignancy that is no longer responding to standard therapy and/or existing therapies, are not likely to achieve clinical benefit and/or the patient declines to receive standard treatment such as chemotherapy.

2. Age 18+

3. Prior history of other malignancies/cancers are allowed if treated over 5 years prior to starting therapy and there is no evidence that the disease returned.

4. Patients with leukemias or myelodysplastic syndrome are not eligible.

Specialty Area(s)

Trial Location

West 168th Street
New York, NY 10032
United States